Sign in

University of Minnesota Infectious Diseases

@umn-idim.bsky.social
4.2K followers 42 following 259 posts

Official account of the U of M Infectious Diseases and International Medicine Division. Posting anything under the #IDSky 🦠🧫🧬🔬📚

PostsRepliesMedia
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 21/09/2026
Proud to have our Orthopedic ID faculty lecturing alongside other faculty from leading universities at at the upcoming AAOS course, Oct 8–9, 2026! 🩺 Gain critical updates on infection prevention, diabetic foot care, complex microbiology, and bacteriophage therapy. www.aaos.org/education/co...
121
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 25/08/2026
Vaccines save lives
0202
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 25/08/2026
Point-of-care CD4 testing is critical for identifying Advanced HIV Disease, but can a fingerprick match a venous draw? 🩸 The assay our faculty Dr. Rajasingham and team validated, showed 95.5% agreement (149/156) across sample types at the 200 cells/μL cutoff. #IDSky
academic.oup.com
Concordance Between Fingerprick and Venous Whole Blood CD4 Counts Using the Visitect CD4 Advanced disease platform
The high level of agreement between Visitect CD4 Advanced Disease platform via fingerprick versus venous whole blood suggests that fingerprick may allow fo
010
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 18/08/2026
#IDSky #HIV #Tuberculosis Our team completed a PK study of adults with advanced HIV taking once-daily dolutegravir and fluconazole alongside 🧬1HP (1-month daily isoniazid + rifapentine) 📊
academic.oup.com
Once-Daily Dolutegravir–Based Antiretroviral Therapy Among Adults With Advanced HIV Disease Receiving 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis-Preventive Therapy and Fluconazole for...
Among adults treated for HIV-associated cryptococcosis, coadministration of 1-month daily isoniazid/rifapentine (1HP) modestly reduced dolutegravir trough
130
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 12/08/2026
New study by faculty Dr. Fontana & colleagues: They evaluated a 2-dose vs 1-dose High-Dose flu vaccine strategy in solid organ transplant recipients. Exploratory analysis showed a significant antibody boost following the 2nd dose for most flu strains. Safe, well-tolerated, & promising! 🔬 #IDSky
academic.oup.com
A Randomized, Double-Blind Clinical Trial of One vs. Two Doses of High-Dose Influenza Vaccine in Solid Organ Transplant Recipients
AbstractBackground. Solid organ transplant recipients (SOTRs) exhibit suboptimal immune responses to standard-dose (SD) influenza vaccines. High-dose (HD)
040
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 29/07/2026
Even with viral suppression, serious non-AIDS events remain a risk in HIV. Our cross-site multi-omic analysis reveals high SNAE risk links to gut dysbiosis. This gut microbe could be a key therapeutic target to reduce inflammation. 🔬🧬 #IDSky
insight.jci.org
JCI Insight - Multi-omics links microbial dysbiosis, systemic inflammation, and metabolomic disruptions to SNAE risk in treated HIV
000
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 29/07/2026
New multi-center research by faculty Dr. Obeid, Dr. Young & colleagues highlights severe challenges in treating refractory HSV in stem cell transplant recipients. With high acyclovir resistance & drug toxicity, their findings stress the urgent need for safer, oral antivirals. #IDSky
academic.oup.com
Refractory Mucocutaneous Infections by Herpes Simplex Virus (HSV) in Hematopoietic Cell Transplant Recipients: A Real-world, Multicenter Study
A total of 55.2% HCT recipients with refractory HSV healed completely at a median of 38 days of therapy. Seventy-five percent of patients received foscarne
163
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 11/07/2026
Benchmarking hospital antibiotic use isn't apples-to-apples. Dr. Drekonja & team developed new Risk-Standardized Ratios (RSR) to adjust for patient case-mixes. The study shows these new metrics offer a clearer look at stewardship than standard SAAR metrics. 🩺📊 #IDSky #MedSky
cambridge.org
Development of risk-standardized metrics for benchmarking hospitals on their inpatient antibiotic use | Infection Control & Hospital Epidemiology | Cambridge Core
Development of risk-standardized metrics for benchmarking hospitals on their inpatient antibiotic use
060
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 23/06/2026
New research from our HIV team in Uganda reveals that TB meningitis survival is linked to the upregulation of adaptive immunity & restraint of specific innate pathways. The data suggests moving away from broad corticosteroids toward targeted immunomodulators to save lives. 🔬 #IDSky
academic.oup.com
Cerebrospinal fluid transcriptional immune pathways linked to survival in HIV-associated tuberculous meningitis
In HIV-associated tuberculous meningitis, short-term survival was associated with upregulation of adaptive immune pathways – including T-cell, B-cell, NK c
030
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 20/06/2026
New research from HIV study group: HLA gene variations & cryptococcal disease risk in Ugandan individuals with HIV. While overall findings were neutral after corrections, the HLA-DPB1*04:01 allele showed potential protective trends, revealing 121 viable peptides for future study #IDSky
sciencedirect.com
Investigation of human leukocyte antigen alleles as risk factors for cryptococcal disease in Ugandan individuals with HIV
Cryptococcus neoformans is an opportunistic fungal infection and a leading cause of HIV-associated meningitis, contributing significantly to AIDS-rela…
110
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 15/06/2026
New economic modeling from Dr. Rajasingham & team evaluates the cost-effectiveness of traditional Fecal Microbiota Transplantation (FMT) vs. newer, FDA-approved commercial microbiota therapies for recurrent C. diff infections. 🔬 #IDSky
academic.oup.com
Cost-effectiveness of Commercial or Traditional Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection
Using a Markov model, we compared traditional fecal microbiota transplantation (FMT) and commercial, Food and Drug Administration (FDA) approved microbiota
121
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 13/06/2026
Untreated HIV-associated tuberculous meningitis is almost universally fatal. New work from Dr. Radha Rajasingham & team shows that Xpert Ultra diagnostic testing is highly cost-effective in Zambia ($242.76/QALY), supporting WHO guidelines for high-burden settings. #IDSky
academic.oup.com
Cost-effectiveness Analysis of Xpert MTB/RIF Ultra for the Diagnosis of HIV-Associated Tuberculous Meningitis
This study evaluates whether cerebrospinal fluid (CSF) Xpert Ultra MTB/RIF testing is cost-effective for diagnosing HIV-associated tuberculous meningitis i
051
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 09/06/2026
New diagnostic stewardship research from faculty Dr. Drekonja & team at VA hospitals. By using clinician education & feedback, they reduced unnecessary preoperative urine cultures in asymptomatic patients from 20.7% to 12.9%—with ortho dropping from 18.7% to 7.4%. 📉 #IDSky #MedSky
cambridge.org
An education with audit and targeted feedback intervention to de-implement preoperative surgical urine cultures: a multi-center quasi-experimental study | Infection Control & Hospital Epidemiology...
An education with audit and targeted feedback intervention to de-implement preoperative surgical urine cultures: a multi-center quasi-experimental study
052
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 08/06/2026
New data from ACTIV-6 trial: The team evaluated whether a 14-day course of metformin prevents Long COVID in low-risk outpatients. While it didn't meet the strict efficacy threshold for self-reported symptoms at Day 180, metformin did reduce clinician-diagnosed Long COVID by about 50%. 🔬 #IDSky
academic.oup.com
Metformin on the Presence of COVID-19 Symptoms 6 Months after Infection: The ACTIV-6 Randomized Clinical Trial
Treating acute COVID-19 with 14 days of metformin has a 63–98% probability of cutting the risk in half of having any symptoms, more severe symptoms, or a c
062
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 06/06/2026
New from our faculty: Despite expanded screening & HIV treatment access in Uganda (2017-2022), cryptococcal meningitis risks remain high. 58% of the 2022 advanced HIV cohort were completely ART-naïve, showing patients still present to care too late. We must refine screening to save lives. #IDSky
journals.plos.org
Change in plasma cryptococcal antigen titers in Uganda among outpatients with advanced HIV disease from 2017 to 2022 with rollout of national cryptococcal screening
Introduction Cryptococcal meningitis causes an estimated 19% of AIDS-related deaths globally and is the leading cause of meningitis in adults with HIV. Subclinical infection with cryptococcal antigen ...
021
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 03/06/2026
A new NEJM study highlights ensitrelvir, a post-exposure pill that cut COVID-19 infection risk from 9% to <3% in household contacts. UMN ID’s Dr. David Boulware weighs in on this promising new preventative tool for high-risk folks. 🧬 #MedSky #COVID19 #IDSky
smithsonianmag.com
This Pill Can Prevent You From Getting Covid-19 After Exposure to the Disease-Causing Virus, According to a Clinical Trial
The drug showed promising results in an international study involving nearly 2,400 participants, and the U.S. Food and Drug Administration is expected to make an approval decision for it in June
051
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 02/06/2026
New research from Dr. Alon Herschhorn’s lab looks at the future of long-acting HIV-1 therapies! 🔬 Broadly neutralizing antibodies are promising, but we need scalable genotypic testing to accurately predict viral resistance before clinical rollout. #UMNProud #IDSky #AcademicSky
nature.com
Genotypic challenges in implementing broadly neutralizing antibody-based long-acting HIV-1 therapies - Communications Medicine
Tao et al. review clinical and experimental data linking HIV-1 Env sequence features to reduced broadly neutralizing Ab susceptibility. While genotypic analysis identifies many predictors of reduced s...
041
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 01/06/2026
Check out a new paper from our faculty and colleagues from 9 academic medical centers!
031
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 12/05/2026
Huge news for the #IDSky community! 🧬 Dr. Leuck and fellow IDSA CREW members have launched a new Infectious Diseases Fellowship Curriculum. This toolkit is designed to streamline administration and improve educational outcomes based on 2025 national survey data.
academic.oup.com
Validate User
021
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 11/05/2026
New Research: Telehealth-enabled provider-to-provider models are a game changer for rural healthcare. 🌐 The VAST initiative from our VA ID colleagues with 10 rural medical centers showed 80% acceptance for antibiotic recommendations. #IDSky 🩺✨
cambridge.org
Recommendations made and accepted by a telehealth-enabled Antimicrobial Stewardship program implemented at rural veterans affairs medical centers | Infection Control &amp; Hospital Epidemiology | Camb...
Recommendations made and accepted by a telehealth-enabled Antimicrobial Stewardship program implemented at rural veterans affairs medical centers
011
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 07/05/2026
We can’t believe this needs to be said. Ivermectin does not work against hantavirus. 🧬 #Wellness
0336
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 05/05/2026
🚨 New research alert! For early postoperative spinal implant infections (PSII) managed with debridement and implant retention, is longer antibiotic therapy always better? Our team, alongside 9 other academic centers, evaluated 499 patients to find out. #IDSky
academic.oup.com
Antibiotic Duration after Debridement and Implant Retention for Early Postoperative Spinal Implant Infections: A Multicenter Cohort Study
In this multicenter retrospective cohort of 499 patients with early postoperative spinal implant infection managed by debridement and implant retention, ex
272
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 30/04/2026
How do structured OPAT fit into the future of value-based care? Only a fraction of OPAT activities are covered under standard CMS coding schemes. We compared patient charges 90 days before and after index OPAT admissions before and after implementing pharmacist-led reconciliation. #IDSky #Medsky
cambridge.org
Cost avoidance analysis of outpatient parenteral antimicrobial therapy (OPAT) plan reconciliation for patients enrolled in value-based payment models at an academic hospital | Antimicrobial Stewardshi...
Cost avoidance analysis of outpatient parenteral antimicrobial therapy (OPAT) plan reconciliation for patients enrolled in value-based payment models at an academic hospital - Volume 6 Issue 1
100
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 21/04/2026
Currently, the framework is heavily oriented toward antibacterial resistance, leaving antifungal resistance (AFR) dangerously neglected. Faculty member, Dr. David Boulware, is among the experts advocating for the immediate integration of AFR into these global One Health commitments. #IDSky
nature.com
Closing the gap on antifungal resistance - Nature Medicine
Drug-resistant fungal disease must be addressed in the 2026 update to the Global Action Plan on Antimicrobial Resistance
021
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 19/04/2026
It’s been an incredible week for our team in Munich at #ESCMIDGlobal2026! 🇩🇪 We’ve had the opportunity to present our latest research, dive into deep discussions on global health, and reconnect with colleagues from across the field. #IDSky
0121
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 17/04/2026
Happy #FollowFriday! 🧪 If your "Infectious Disease" starter pack is looking a little thin, give us a follow. #IDSky #MedSky
040
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 17/04/2026
📊 New work from @drboulware.bsky.social looks at Early Fungicidal Activity (EFA) in Cryptococcal meningitis. The 2-step approach is preferred for EFA, particularly when early culture sterility is common. Linear mixed models can bias estimates toward the null. #IDSky #MedSky
academic.oup.com
Assessing Statistical Methods for Estimating the Cerebrospinal Fluid Early Fungicidal Activity as an Endpoint for Cryptococcal Meningitis Clinical Trials: A Systematic Review and Simulation Study
AbstractBackground. Cryptococcal meningitis is a life-threatening infection of the central nervous system. Early fungicidal activity (EFA), which measures
020
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 14/04/2026
The global landscape of liver cancer is undergoing a major transition. 🦠➡️🍔 • Incidence remains highest in East Asia & Africa. • Etiology is shifting from predominantly infection-related to metabolic & alcohol-associated. • Rural-urban disparities are widening the gap in outcomes. #MedSky
journals.lww.com
000
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 15/03/2026
#UMNProud
011
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 15/03/2026
🚨A new study by incoming fellow Dr. Okuno, mentored by faculty Dr. Boulware and Dr. Bahr, evaluates the association between therapeutic LPs and survival in patients with Cryptococcal Meningitis. The Findings: repeat LPs are a life-saving intervention across diverse patient populations. #IDSky
academic.oup.com
Lumbar Puncture Frequency and Patient Survival Among Persons Hospitalized with Cryptococcal Meningitis in the United States
Abstract. Elevated intracranial pressure contributes to high mortality in cryptococcal meningitis. We evaluated the association between therapeutic lumbar
086
Reposted by University of Minnesota Infectious Diseases
PIDS @pidsociety.bsky.social · 04/03/2026
State of the Art - CMV: Dr. Mark Schleiss @umn-idim.bsky.social presents 'Newborn Screening for Cytomegalovirus (cCMV) Infection Universal, Targeted, Expanded-Targeted or None-of-the-Above?' with how states are approaching screening. #stjudepids2026
131
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 03/03/2026
New research from our faculty: antibiotic allergy labels in transplant patients are linked to C. diff infections, more antibiotic use & longer hospital stays, and they may be preventable. 🔬 #IDSky #MedSky
onlinelibrary.wiley.com
The Clinical Impact of Antibiotic Allergy Labels on One‐Year Outcomes of Solid Organ Transplant Recipients
Antibiotic allergy labels (AALs) are common and often incorrect. They have many potential impacts, including the use of broader-spectrum antibiotics and suboptimal treatment of infections. The impact....
074
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 10/02/2026
Can we improve TB preventive therapy (TPT) for those with advanced HIV? 🏥 A new phase-3 trial from @drboulware.bsky.social and colleagues evaluated two strategies for the 1-month 1HP (rifapentine + isoniazid) regimen in patients with cryptococcal meningitis. #IDSky
thelancet.com
Inpatient initiation of tuberculosis preventive therapy with 1 month of isoniazid and rifapentine for adults with advanced HIV disease and cryptococcal meningitis (IMPROVE): a non-inferiority, randomi...
1HP initiation before hospital discharge was non-inferior to outpatient initiation among adults with AHD and cryptococcosis. These data suggest that following exclusion of active tuberculosis disease,...
171
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 01/02/2026
ATLAS trial by faculty Dr. David Boulware and colleagues, studied TB treatment timing in people with HIV & sepsis in East Africa. Overall mortality unchanged, but early standard-dose TB therapy saved lives in confirmed TB cases. #IDSky #MedSky
thelancet.com
Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial
Among all participants with HIV-related sepsis, 28-day mortality was not significantly reduced with immediate or high-dose antituberculosis therapy. In the subgroup with later confirmed tuberculosis, ...
090
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 30/01/2026
Faculty research spotlight: Dr. Rajasingham and colleagues studied point-of-care CD4 testing for advanced HIV in Uganda. Visitect CD4 enabled faster ART initiation with similar 24-week survival and retention-in-care at comparable cost. #IDSky
onlinelibrary.wiley.com
140
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 29/01/2026
Faculty highlight: Dr. Dimitri Drekonja and colleagues conducted a study showing AI can streamline infection surveillance after cardiac device procedures—reducing chart review time from ~25 to 5–7 minutes, with excellent accuracy and needed human oversight. #IDSky #AI
cambridge.org
Leveraging a large language model to support expansion of surveillance activities to include cardiovascular implantable device infections in a large, integrated national healthcare system | Infection ...
Leveraging a large language model to support expansion of surveillance activities to include cardiovascular implantable device infections in a large, integrated national healthcare system
020
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 23/01/2026
New faculty research in @ofidjournal.bsky.social shows that headache plus high plasma CrAg titer is the strongest predictor of cryptococcal meningitis in people with HIV. When titers are unavailable, combining neurologic symptoms improves triage decisions. #IDSky #MedSky
academic.oup.com
Headache as a predictor of cryptococcal meningitis in ambulatory patients with symptomatic HIV-associated cryptococcal antigenemia
AbstractBackground. People with HIV-associated cryptococcal antigenemia are at high risk for meningitis and death. In resource-limited settings, lumbar pun
060
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 15/01/2026
University of Minnesota Infectious Diseases researchers presented multiple abstracts at #IDWeek2025, spanning antimicrobial stewardship, global health, and orthopedic infections. Proud of our faculty and trainees. #IDSky
130
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 12/01/2026
New work from Dr. Fontana and colleagues examines induction immunosuppression after BK virus–associated nephropathy–related graft loss. Depletional vs nondepletional induction showed no difference in 10-year graft or patient survival. 🧬🩺 #IDSky onlinelibrary.wiley.com/doi/10.1111/...
onlinelibrary.wiley.com
Induction Regimens and Kidney Re‐Transplant Outcomes after BK Nephropathy–Related Graft Loss: A U.S. Cohort Study
This study investigated the association between induction type and long-term outcomes in kidney retransplant recipients who experienced graft loss due to BK virus–associated nephropathy (BKVAN). Usin...
040
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 21/12/2025
A late reflection on @idweek.bsky.social , but a memorable start to the meeting. The opening plenary with Drs. Michael Osterholm and Ruth Lynfield set the tone on preparedness, public trust, and why public health partnerships matter. #IDSky
140
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 20/12/2025
Prolonged antibiotics may not improve outcomes in early spinal implant infections. At IDWeek, SPIRIT researchers showed no benefit to therapy >12 weeks when optimal surgical source control is achieved. #IDSky
healio.com
Prolonged antibiotic therapy for spinal implant infection may not improve outcomes
ATLANTA &mdash; Results presented at IDWeek showed prolonged antibiotic therapy beyond 12 weeks may not improve outcomes for early postoperative spinal implant infections.&ldquo;Shorter, standardized ...
060
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 18/12/2025
High-dose rifampin did not improve survival in adult tuberculous meningitis. In a trial across 3 countries, 6-month mortality was similar to standard dosing, with more liver injury at higher doses. Important evidence for TB care from @natebahrid.bsky.social @drboulware.bsky.social . #IDSky
nejm.org
Trial of High-Dose Oral Rifampin in Adults with Tuberculous Meningitis | NEJM
Tuberculous meningitis is often lethal, and many survivors have disabilities despite antimicrobial treatment and adjunctive glucocorticoid therapy. Standard-dose rifampin has limited central nervou...
0116
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 09/12/2025
Musculoskeletal infections make up a major share of the ID clinical workload, yet many clinicians feel underprepared for their complexity. Faculty member Dr. Tai created an online resource to make high-yield MSK ID knowledge accessible and practical for all learners. #IDSky
academic.oup.com
Enhancing the Care of Patients With Bone and Joint Infections Through Educational Interventions
Abstract. Musculoskeletal infections represent a significant proportion of the clinical workload for infectious diseases (ID) providers, often presenting c
2101
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 04/12/2025
Celebrating Match Day! 🎉 Welcome to our future colleagues. We can’t wait for you to join the University of Minnesota ID team! #Match2025 #IDSky
Welcome to our fellows.
060
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 03/12/2025
The hepatitis B birth dose is safe, effective, and a critical shield against lifelong infection. Delaying it puts infants at risk for preventable, chronic HBV. Universal newborn vaccination saves lives and remains essential public health practice. #HepatitisB #VaccinesWork #IDSky
02814
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 02/12/2025
New HIV vaccine research shows that escalating dose mRNA priming plus protein VLP boosts produced strong antibody responses in rabbits. Broad neutralization remains difficult and continued innovation is essential. #HIVresearch #UMNproud #IDSky
mdpi.com
060
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 15/11/2025
New research from Dr. Debes: In a Colombian cohort with Metabolic Associated Steatotic Liver Disease, the PNPLA3 risk allele was highly prevalent and strongly linked to advanced fibrosis and cirrhosis. Gene combinations also increased risk. #GISky
jcehepatology.com
Genetic Analysis of Metabolic-associated Steatosis Liver Disease in a Colombian Cohort
Numerous studies have identified genetic variations linked to the development and progression of Metabolic Associated Steatosis Liver Disease (MASLD), but their relevance is not completely understood ...
030
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 12/11/2025
New research from Dr. Alon Herschhorn and team reveals a more efficient way to produce the HIV-1 gp120 protein, a key component for vaccine and viral entry studies. The stable cell line method yields 50× more protein than traditional approaches. #IDSky
journals.asm.org
Highly efficient production of HIV-1AD8 gp120 in mammalian cells | Journal of Virology
There are approximately 40.8 million people living with HIV-1 (PLWH) worldwide, with an estimate of about 1.3 million new HIV-1 infections in 2024, highlighting the urgent need for an effective HIV-1 ...
030
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 10/11/2025
@nejm.org + @cidrap.bsky.social are launching Public Health Alerts — a new rapid-report platform to rival MMWR. Free, timely, and aimed at practitioners & researchers alike. #IDSky
statnews.com
NEJM and public health group are launching rival to CDC’s MMWR publication
Two institutions are coming together to create an alternative to the CDC’s vaunted Morbidity and Mortality Weekly Report
194
University of Minnesota Infectious Diseases @umn-idim.bsky.social · 10/11/2025
Mortality from advanced HIV disease remains high. The NIRVANA trial, led by Dr. Caleb Skipper and colleagues, tests whether treating CMV viraemia with valganciclovir can save lives. A phase 2b study now underway in Uganda and South Africa. #IDSky #Research
royalsocietypublishing.org
040